Australian-US biotech Opthea Ltd has reported disappointing phase 3 results with its lead drug for vision-robbing disease wet age-related macular degeneration (AMD), throwing its future into doubt.

AI company Anthropic and the Gates Foundation have said they will provide $200 million in funding for a programme to support the development of AI for "health, life sciences, education, and economic ...

Emboldened by strong data for its oral IL-23 inhibitor icotrokinra in psoriasis, Johnson & Johnson has said it will see if it can outperform its big-selling injectable therapy Stelara in a ...

President Donald Trump's plan to introduce a most favoured nation (MFN) system of drug pricing controls is not quite what he first said it would be, according to a statement from the administration.

Bayer chief executive Bill Anderson has said that newer product launches have offset the decline in sales of anticoagulant Xarelto in the first quarter, and he is confident that this will continue ...

The head-to-head rivalry between Novo Nordisk and Eli Lilly in oral GLP-1 agonists for weight loss has come to the fore this week, with both companies presenting new data at the European Congress on ...

International reliance is a mechanism whereby certain medical devices could access the UK market more quickly if they have already been approved by a comparable regulator, rather than undergoing a ...

Bill Gates has made a $50 million donation to the Dementia Discovery Fund, a collaboration between pharma, the UK government and the charity Alzheimer’s Research UK, that aims to challenge the ...

China has such a dominant position in active pharmaceutical ingredient (API) production that there is a risk it could "weaponise" access, according to a new congressional report. The document, from ...

Neuroscience specialist Lundbeck has agreed to buy Longboard Pharmaceuticals for $2.6 billion, expanding its pipeline with an epilepsy drug tipped as a future blockbuster. The Danish drugmaker has ...

AstraZeneca has claimed UK approval for a new version of its respiratory triple therapy Trixeo Aerosphere that contains a propellant with a massively reduced global warming potential (GWP). The drug – ...

Henry Gosebruch, pictured here during his time at Neumora, is replacing Paul Stoffels as CEO of Galapagos. Just a few months after announcing a plan to separate its drug and cell therapy businesses ...